Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics, a biotechnology company specializing in targeted and immuno-oncology therapeutics, has announced the initiation of Part B of the DeFianCe study for DKN-01 in colorectal cancer patients. This study aims to assess the effectiveness of Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, when combined with standard care bevacizumab and chemotherapy as a second-line treatment for advan..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 13.
  • textsms

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Palisade Bio, a biopharmaceutical company focused on gastrointestinal complications, has announced the completion of patient enrollment in its LB1148 dose optimization study. The study aims to generate valuable data on pharmacokinetics and pharmacodynamics across multiple doses in healthy adult volunteers. This milestone brings Palisade Bio closer to obtaining Phase 2 topline data for the preven..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms